Myo-inositol trispyrophosphate prevents right ventricular failure and improves survival in monocrotaline-induced pulmonary hypertension in the rat.
hypoxia
monocrotaline
pulmonary hypertension
right ventricular failure
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
revised:
17
04
2024
received:
16
11
2023
accepted:
19
05
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
aheadofprint
Résumé
Pulmonary hypertension (PH) results from pulmonary vasculopathy, initially leading to a compensatory right ventricular (RV) hypertrophy, and eventually to RV failure. Hypoxia can trigger both pulmonary vasculopathy and RV failure. Therefore, we tested if myo-inositol trispyrophosphate (ITPP), which facilitates oxygen dissociation from haemoglobin, can relieve pulmonary vasculopathy and RV hypoxia, and eventually prevent RV failure and mortality in the rat model of monocrotaline-induced PH. Rats were injected with monocrotaline (PH) or saline (control) and received ITPP or placebo for 5 weeks. Serial echocardiograms were obtained to monitor the disease, pressure-volume loops were recorded and evaluated, myocardial pO ITPP reduced PH-related mortality. It had no effect on progressive increase in pulmonary vascular resistance, yet significantly relieved intramyocardial RV hypoxia, which was associated with improvement of RV function and reduction of RV wall stress. ITPP also tended to prevent increased hypoxia inducible factor-1α expression in RV cardiac myocytes but did not affect RV capillary density. Our study suggests that strategies aimed at increasing oxygen delivery to hypoxic RV in PH could potentially be used as adjuncts to other therapies that target pulmonary vessels, thus increasing the ability of the RV to withstand increased afterload and reducing mortality. ITPP may be one such potential therapy.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Pulmonary hypertension (PH) results from pulmonary vasculopathy, initially leading to a compensatory right ventricular (RV) hypertrophy, and eventually to RV failure. Hypoxia can trigger both pulmonary vasculopathy and RV failure. Therefore, we tested if myo-inositol trispyrophosphate (ITPP), which facilitates oxygen dissociation from haemoglobin, can relieve pulmonary vasculopathy and RV hypoxia, and eventually prevent RV failure and mortality in the rat model of monocrotaline-induced PH.
EXPERIMENTAL APPROACH
METHODS
Rats were injected with monocrotaline (PH) or saline (control) and received ITPP or placebo for 5 weeks. Serial echocardiograms were obtained to monitor the disease, pressure-volume loops were recorded and evaluated, myocardial pO
KEY RESULTS AND CONCLUSIONS
CONCLUSIONS
ITPP reduced PH-related mortality. It had no effect on progressive increase in pulmonary vascular resistance, yet significantly relieved intramyocardial RV hypoxia, which was associated with improvement of RV function and reduction of RV wall stress. ITPP also tended to prevent increased hypoxia inducible factor-1α expression in RV cardiac myocytes but did not affect RV capillary density.
IMPLICATIONS
CONCLUSIONS
Our study suggests that strategies aimed at increasing oxygen delivery to hypoxic RV in PH could potentially be used as adjuncts to other therapies that target pulmonary vessels, thus increasing the ability of the RV to withstand increased afterload and reducing mortality. ITPP may be one such potential therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Centre
ID : 2019/35/B/NZ5/04432
Organisme : National Science Centre
ID : 2022/45/N/NZ5/03399
Organisme : Centre of Postgraduate Medical Education mini Grant 2022
Informations de copyright
© 2024 British Pharmacological Society.
Références
Alexander, S. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Buneman, O. P., Cidlowski, J. A., Christopoulos, A., Davenport, A. P., Fabbro, D., Spedding, M., Striessnig, J., Davies, J. A., Ahlers‐Dannen, K. E., … Zolghadri, Y. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and other protein targets. British Journal of Pharmacology, 178(Suppl 1), S1–S26. https://doi.org/10.1111/bph.15537
Balestra, G. M., Mik, E. G., Eerbeek, O., Specht, P. A. C., van der Laarse, W. J., & Zuurbier, C. J. (2015). Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: Mitochondrial inhibition as driver of cardiac failure? Respiratory Research, 16, 6. https://doi.org/10.1186/s12931-015-0178-6
Bogaard, H. J., Natarajan, R., Henderson, S. C., Long, C. S., Kraskauskas, D., Smithson, L., Ockaili, R., McCord, J. M., & Voelkel, N. F. (2009). Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation, 120, 1951–1960. https://doi.org/10.1161/CIRCULATIONAHA.109.883843
Boucherat, O., Agrawal, V., Lawrie, A., & Bonnet, S. (2022). The latest in animal models of pulmonary hypertension and right ventricular failure. Circulation Research, 130, 1466–1486. https://doi.org/10.1161/CIRCRESAHA.121.319971
Braile, M., Marcella, S., Cristinziano, L., Galdiero, M. R., Modestino, L., Ferrara, A. L., Varricchi, G., Marone, G., & Loffredo, S. (2020). VEGF‐A in cardiomyocytes and heart diseases. International Journal of Molecular Sciences, 21, 5294. https://doi.org/10.3390/ijms21155294
Brown, M. B., Neves, E., Long, G., Graber, J., Gladish, B., Wiseman, A., Owens, M., Fisher, A. J., Presson, R. G., Petrache, I., Kline, J., & Lahm, T. (2017). High‐intensity interval training, but not continuous training, reverses right ventricular hypertrophy and dysfunction in a rat model of pulmonary hypertension. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 312, R197–R210.
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Sobey, C. G., Stanford, S. C., Teixeira, M. M., Wonnacott, S., & Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology, 175, 987–993. https://doi.org/10.1111/bph.14153
Drake, J. I., Bogaard, H. J., Mizuno, S., Clifton, B., Xie, B., Gao, Y., Dumur, C. I., Fawcett, P., Voelkel, N. F., & Natarajan, R. (2011). Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 45, 1239–1247. https://doi.org/10.1165/rcmb.2010-0412OC
Duarte, C. D., Greferath, R., Nicolau, C., & Lehn, J.‐M. (2010). Myo‐inositol Trispyrophosphate: A novel allosteric effector of hemoglobin with high permeation selectivity across the red blood cell plasma membrane. Chembiochem, 11, 2543–2548. https://doi.org/10.1002/cbic.201000499
El Hafny‐Rahbi, B., Brodaczewska, K., Collet, G., Majewska, A., Klimkiewicz, K., Delalande, A., Grillon, C., & Kieda, C. (2021). Tumour angiogenesis normalized by myo‐inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response. Journal of Cellular and Molecular Medicine, 25, 3284–3299. https://doi.org/10.1111/jcmm.16399
Fylaktakidou, K. C., Lehn, J.‐M., Greferath, R., & Nicolau, C. (2005). Inositol tripyrophosphate: A new membrane permeant allosteric effector of haemoglobin. Bioorganic & Medicinal Chemistry Letters, 15, 1605–1608. https://doi.org/10.1016/j.bmcl.2005.01.064
Gómez, A., Bialostozky, D., Zajarias, A., Santos, E., Palomar, A., Martínez, M. L., & Sandoval, J. (2001). Right ventricular ischemia in patients with primary pulmonary hypertension. Journal of the American College of Cardiology, 38, 1137–1142. https://doi.org/10.1016/S0735-1097(01)01496-6
Grishko, V., Solomon, M., Breit, J. F., Killilea, D. W., LeDoux, S. P., Wilson, G. L., & Gillespie, M. N. (2001). Hypoxia promotes oxidative base modifications in the pulmonary artery endothelial cell VEGF gene. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 15, 1267–1269. https://doi.org/10.1096/fj.00-0755fje
Hessel, M. H. M., Steendijk, P., den Adel, B., Schutte, C. I., & van der Laarse, A. (2006). Characterization of right ventricular function after monocrotaline‐induced pulmonary hypertension in the intact rat. American Journal of Physiology. Heart and Circulatory Physiology, 291, H2424–H2430.
Hoeper, M. M., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg‐Maitland, M., McLaughlin, V. V., Preston, I. R., Souza, R., Waxman, A. B., Grünig, E., Kopeć, G., Meyer, G., Olsson, K. M., Rosenkranz, S., Xu, Y., Miller, B., Fowler, M., Butler, J., Koglin, J., … STELLAR Trial Investigators. (2023). Phase 3 trial of Sotatercept for treatment of pulmonary arterial hypertension. New England Journal of Medicine, 388, 1478–1490. https://doi.org/10.1056/NEJMoa2213558
Huang, Y., Hickey, R. P., Yeh, J. L., Liu, D., Dadak, A., Young, L. H., Johnson, R. S., & Giordano, F. J. (2004). Cardiac myocyte‐specific HIF‐1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 18, 1138–1140. https://doi.org/10.1096/fj.04-1510fje
Humbert, M., Guignabert, C., Bonnet, S., Dorfmüller, P., Klinger, J. R., Nicolls, M. R., Olschewski, A. J., Pullamsetti, S. S., Schermuly, R. T., Stenmark, K. R., & Rabinovitch, M. (2019). Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives. European Respiratory Journal, 53, 1801887. https://doi.org/10.1183/13993003.01887-2018
Humbert, M., McLaughlin, V., Gibbs, J. S. R., Gomberg‐Maitland, M., Hoeper, M. M., Preston, I. R., Souza, R., Waxman, A., Escribano Subias, P., Feldman, J., Meyer, G., Montani, D., Olsson, K. M., Manimaran, S., Barnes, J., Linde, P. G., de Oliveira Pena, J., & Badesch, D. B. (2021). Sotatercept for the treatment of pulmonary arterial hypertension. New England Journal of Medicine, 384, 1204–1215. https://doi.org/10.1056/NEJMoa2024277
Izumiya, Y., Shiojima, I., Sato, K., Sawyer, D. B., Colucci, W. S., & Walsh, K. (2006). Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension, 47, 887–893. https://doi.org/10.1161/01.HYP.0000215207.54689.31
Kido, M., du, L., Sullivan, C. C., Li, X., Deutsch, R., Jamieson, S. W., & Thistlethwaite, P. A. (2005). Hypoxia‐inducible factor 1‐alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. Journal of the American College of Cardiology, 46, 2116–2124. https://doi.org/10.1016/j.jacc.2005.08.045
Kieda, C., El Hafny‐Rahbi, B., Collet, G., Lamerant‐Fayel, N., Grillon, C., Guichard, A., Dulak, J., Jozkowicz, A., Kotlinowski, J., Fylaktakidou, K. C., Vidal, A., Auzeloux, P., Miot‐Noirault, E., Beloeil, J. C., Lehn, J. M., & Nicolau, C. (2013). Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. Journal of Molecular Medicine (Berlin, Germany), 91, 883–899. https://doi.org/10.1007/s00109-013-0992-6
Kieda, C., Greferath, R., Crola da Silva, C., Fylaktakidou, K. C., Lehn, J.‐M., & Nicolau, C. (2006). Suppression of hypoxia‐induced HIF‐1alpha and of angiogenesis in endothelial cells by myo‐inositol trispyrophosphate‐treated erythrocytes. Proceedings of the National Academy of Sciences of the United States of America, 103, 15576–15581. https://doi.org/10.1073/pnas.0607109103
Klima, U. P., Guerrero, J. L., & Vlahakes, G. J. (1999). Myocardial perfusion and right ventricular function. Annals of Thoracic and Cardiovascular Surgery: Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 5, 74–80.
Knutson, A. K., Williams, A. L., Boisvert, W. A., & Shohet, R. V. (2021). HIF in the heart: Development, metabolism, ischemia, and atherosclerosis. The Journal of Clinical Investigation, 131, e137557. https://doi.org/10.1172/JCI137557
Kosanovic, D., Kojonazarov, B., Luitel, H., Dahal, B. K., Sydykov, A., Cornitescu, T., Janssen, W., Brandes, R. P., Davie, N., Ghofrani, H. A., Weissmann, N., Grimminger, F., Seeger, W., & Schermuly, R. T. (2011). Therapeutic efficacy of TBC3711 in monocrotaline‐induced pulmonary hypertension. Respiratory Research, 12, 87. https://doi.org/10.1186/1465-9921-12-87
Kotch, L. E., Iyer, N. V., Laughner, E., & Semenza, G. L. (1999). Defective vascularization of HIF‐1alpha‐null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Developmental Biology, 209, 254–267. https://doi.org/10.1006/dbio.1999.9253
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021). Cardiac energy metabolism in heart failure. Circulation Research, 128, 1487–1513. https://doi.org/10.1161/CIRCRESAHA.121.318241
Oknińska, M., el‐Hafny‐Rahbi, B., Paterek, A., Mackiewicz, U., Crola‐da Silva, C., Brodaczewska, K., Mączewski, M., & Kieda, C. (2020). Treatment of hypoxia‐dependent cardiovascular diseases by myo‐inositol trispyrophosphate (ITPP)‐enhancement of oxygen delivery by red blood cells. Journal of Cellular and Molecular Medicine, 24, 2272–2283. https://doi.org/10.1111/jcmm.14909
Oknińska, M., Mackiewicz, U., Zajda, K., Kieda, C., & Mączewski, M. (2022). New potential treatment for cardiovascular disease through modulation of hemoglobin oxygen binding curve: Myo‐inositol trispyrophosphate (ITPP), from cancer to cardiovascular disease. Biomedicine & Pharmacotherapy, 154, 113544. https://doi.org/10.1016/j.biopha.2022.113544
Oknińska, M., Zajda, K., Zambrowska, Z., Grzanka, M., Paterek, A., Mackiewicz, U., Szczylik, C., Kurzyna, M., Piekiełko‐Witkowska, A., Torbicki, A., & Kieda, C. (2024). Role of oxygen starvation in right ventricular decompensation and failure in pulmonary arterial hypertension. JACC. Heart Failure, 11, 235–247.
Oknińska, M., Zambrowska, Z., Zajda, K., Paterek, A., Brodaczewska, K., Mackiewicz, U., Szczylik, C., Torbicki, A., Kieda, C., & Mączewski, M. (2021). Right ventricular myocardial oxygen partial pressure is reduced in monocrotaline‐induced pulmonary hypertension in the rat and restored by myo‐inositol trispyrophosphate. Scientific Reports, 11, 18002. https://doi.org/10.1038/s41598-021-97470-6
Pak, O., Aldashev, A., Welsh, D., & Peacock, A. (2007). The effects of hypoxia on the cells of the pulmonary vasculature. European Respiratory Journal, 30, 364–372. https://doi.org/10.1183/09031936.00128706
Partovian, C., Adnot, S., Eddahibi, S., Teiger, E., Levame, M., Dreyfus, P., Raffestin, B., & Frelin, C. (1998). Heart and lung VEGF mRNA expression in rats with monocrotaline‐ or hypoxia‐induced pulmonary hypertension. The American Journal of Physiology, 275, H1948–H1956. https://doi.org/10.1152/ajpheart.1998.275.6.H1948
Paterek, A., Kępska, M., Kołodziejczyk, J., Leszek, P., Mackiewicz, U., & Mączewski, M. (2018). Acute heart rate‐dependent hemodynamic function of the heart in the post‐myocardial infarction rat model: Change over time. Canadian Journal of Cardiology, 34, 1341–1349. https://doi.org/10.1016/j.cjca.2018.08.009
Piao, L., Fang, Y.‐H., Parikh, K., Ryan, J. J., Toth, P. T., & Archer, S. L. (2013). Cardiac glutaminolysis: A maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. Journal of Molecular Medicine, 91, 1185–1197. https://doi.org/10.1007/s00109-013-1064-7
Pullamsetti, S. S., Mamazhakypov, A., Weissmann, N., Seeger, W., & Savai, R. (2020). Hypoxia‐inducible factor signaling in pulmonary hypertension. The Journal of Clinical Investigation, 130, 5638–5651. https://doi.org/10.1172/JCI137558
Satchwell, T. J., & Toye, A. M. (2021). Band 3, an essential red blood cell hub of activity. Haematologica, 106, 2792–2793. https://doi.org/10.3324/haematol.2021.278643
Schneider, M. A., Linecker, M., Fritsch, R., Muehlematter, U. J., Stocker, D., Pestalozzi, B., Samaras, P., Jetter, A., Kron, P., Petrowsky, H., Nicolau, C., Lehn, J. M., Humar, B., Graf, R., Clavien, P. A., & Limani, P. (2021). Phase Ib dose‐escalation study of the hypoxia‐modifier Myo‐inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. Nature Communications, 12, 3807. https://doi.org/10.1038/s41467-021-24069-w
Shiojima, I., Sato, K., Izumiya, Y., Schiekofer, S., Ito, M., Liao, R., Colucci, W. S., & Walsh, K. (2005). Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. The Journal of Clinical Investigation, 115, 2108–2118. https://doi.org/10.1172/JCI24682
Smith, K. A., Waypa, G. B., Dudley, V. J., Budinger, G. R. S., Abdala‐Valencia, H., Bartom, E., & Schumacker, P. T. (2020). Role of hypoxia‐inducible factors in regulating right ventricular function and remodeling during chronic hypoxia‐induced pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 63, 652–664. https://doi.org/10.1165/rcmb.2020-0023OC
Sree Raman, K., Shah, R., Stokes, M., Walls, A., Woodman, R. J., Perry, R., Walker, J. G., Proudman, S., de Pasquale, C. G., Celermajer, D. S., & Selvanayagam, J. B. (2021). Right ventricular myocardial deoxygenation in patients with pulmonary artery hypertension. Journal of Cardiovascular Magnetic Resonance, 23, 22. https://doi.org/10.1186/s12968-020-00694-0
Strauer, B. E., Beer, K., Heitlinger, K., & Höfling, B. (1977). Left ventricular systolic wall stress as a primary determinant of myocardial oxygen consumption: Comparative studies in patients with normal left ventricular function, with pressure and volume overload and with coronary heart disease. Basic Research in Cardiology, 72, 306–313. https://doi.org/10.1007/BF01906378
Sutendra, G., Dromparis, P., Paulin, R., Zervopoulos, S., Haromy, A., Nagendran, J., & Michelakis, E. D. (2013). A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. Journal of Molecular Medicine, 91, 1315–1327. https://doi.org/10.1007/s00109-013-1059-4
Urboniene, D., Haber, I., Fang, Y.‐H., Thenappan, T., & Archer, S. L. (2010). Validation of high‐resolution echocardiography and magnetic resonance imaging vs. high‐fidelity catheterization in experimental pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology, 299, L401–L412. https://doi.org/10.1152/ajplung.00114.2010
van Wolferen, S. A., Marcus, J. T., Westerhof, N., Spreeuwenberg, M. D., Marques, K. M. J., Bronzwaer, J. G. F., Henkens, I. R., Gan, C. T. J., Boonstra, A., Postmus, P. E., & Vonk‐Noordegraaf, A. (2007). Right coronary artery flow impairment in patients with pulmonary hypertension. European Heart Journal, 29, 120–127. https://doi.org/10.1093/eurheartj/ehm567
Yang, J., Sun, M., Chen, R., Ye, X., Wu, B., Liu, Z., Zhang, J., Gao, X., Cheng, R., He, C., He, J., Wang, X., & Huang, L. (2023). Mitochondria‐associated membrane protein PACS2 maintains right cardiac function in hypobaric hypoxia. iScience, 26, 106328. https://doi.org/10.1016/j.isci.2023.106328